# OnCo record prostate-nepc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/prostate-nepc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "prostate-nepc" ;
  schema:name "Neuroendocrine and small-cell prostate cancer"@en ;
  schema:alternateName "NEPC"@en, "Treatment-emergent neuroendocrine prostate cancer"@en, "t-NEPC"@en, "Small-cell carcinoma of the prostate"@en, "Aggressive variant prostate cancer"@en ;
  schema:description "Neuroendocrine prostate cancer is a form that has stopped depending on the androgen receptor, either from the start or after years of hormone therapy. It no longer shows up on PSA, spreads to the liver and brain, and is treated with the platinum chemotherapy used for small-cell lung cancer."@en ;
  schema:url <https://onco.cc/cancers/prostate-nepc/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Prostate_cancer> ;
  schema:citation <https://en.wikipedia.org/wiki/Prostate_cancer>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459> ;
  onco:tag "subtype-page" ;
  onco:pipeline <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/drugs/mevrometostat/>, <https://onco.cc/drugs/lurbinectedin/>, <https://onco.cc/drugs/ifinatamab-deruxtecan/> ;
  onco:standardOfCare <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/technologies/androgen-deprivation/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/cabazitaxel/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/psma-pet/>, <https://onco.cc/technologies/pet/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/targets/dll3/>, <https://onco.cc/drugs/mevrometostat/>, <https://onco.cc/targets/ezh2/>, <https://onco.cc/drugs/lurbinectedin/> .